Loading

Minutia

June 05, 2024
Start-Up Stadium Session
Cell and Gene Therapy and Genome Editing
5B
Company Description: Minutia is developing a regenerative medicine platform that improves safety and success outcomes of transplanted cells, our first therapy is a functional cure for Type 1 and Insulin Dependent Type 2 Diabetes with a simple outpatient procedure. We have already successfully demonstrated our out-patient transplant procedure in a PI-led Phase 1/2 clinical trial at UCSF, and are progressing our nanoparticle instrumented stem cell platform to enable safety and personalization across the broader cell therapy market.

Minutia
Company Website: http://www.minutia.co

Company HQ City

Oakland

Company HQ State

California

Company HQ Country

United States

CEO/Top Company Official

Katy Digovich
Speakers
Katy Digovich, MBA
CEO
Minutia
Back to Session List

BIO DOUBLE HELIX SPONSOR

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS